Bruker Announces Over 100 Systems Orders Received in the Second Half of 2009 from Global Stimulus Programs
07 January 2010 - 11:00PM
Business Wire
Bruker Corporation (NASDAQ: BRKR) announced today that during
the second half of 2009, the Company has already received over 100
additional systems orders from various global stimulus funding
budgets. This number excludes 51 mass spectrometers delivered to
Japan’s National Police Agency in the first half of 2009 under a
previous supplementary budget.
All five Bruker operating divisions have received stimulus
orders, with most orders for high-end instrumentation, especially
for NMR, pre-clinical MRI, mass spectrometry and X-ray systems.
Bruker estimates that average selling prices of these stimulus
orders were greater than $500,000 per system, with a cumulative
amount of stimulus orders already received in the second half of
2009 greater than $70 million. These orders are expected to result
in revenues primarily in the year 2010, and into the first half of
2011. The Company expects to receive additional orders from various
global stimulus programs, including U.S. ARRA funding, in 2010.
Frank Laukien, President and CEO of Bruker Corporation,
commented: “We are delighted that so many top-notch researchers
around the world have selected high-performance scientific
instruments from Bruker, and we thank our customers for their vote
of confidence.”
Cautionary Statement
Any statements contained in this presentation that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995. Any forward-looking statements contained herein are
based on current expectations, but are subject to risks and
uncertainties that could cause actual results to differ materially
from those projected, including, but not limited to, risks and
uncertainties relating to adverse changes in conditions in the
global economy and volatility in the capital markets, the
integration of businesses we have acquired or may acquire in the
future, changing technologies, product development and market
acceptance of our products, the cost and pricing of our products,
manufacturing, competition, dependence on collaborative partners
and key suppliers, capital spending and government funding
policies, changes in governmental regulations, realization of
anticipated benefits from economic stimulus programs, intellectual
property rights, litigation, and exposure to foreign currency
fluctuations and other risk factors discussed from time to time in
our filings with the Securities and Exchange Commission. These and
other factors are identified and described in more detail in our
filings with the SEC, including, without limitation, our recent
Proxy Statements on Schedule 14A, our annual report on Form 10-K
for the year ended December 31, 2008, our most recent quarterly
reports on Form 10-Q and our current reports on Form 8-K. We
expressly disclaim any intent or obligation to update these
forward-looking statements other than as required by law.
ABOUT BRUKER CORPORATION
For more information about Bruker Corporation, please visit
www.bruker.com.
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024